Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

HAE – Haemonetics Corporation

HAE — Price & Float Short
—— Fair value ★ EPS beat ★ EPS miss —— Target Price
Float Short %

Float Short %

6.81

Margin Of Safety %

-21

Put/Call OI Ratio

0.59

EPS Next Q Diff

0.22

EPS Last/This Y

0.35

EPS This/Next Y

0.47

Price

116.18

Target Price

124.5

Analyst Recom

1.67

Performance Q

47.48

Upside

-61.2%

Beta

0.65

Ticker: HAE




22 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-09-23HAE106.880.322.753586
2026-09-24HAE106.050.320.143597
2026-09-25HAE105.330.313.333719
2026-09-28HAE105.750.311.063725
2026-09-29HAE105.850.310.073755
2026-09-30HAE105.360.313.003781
2026-10-01HAE104.420.310.443783
2026-10-02HAE104.670.310.073792
2026-10-05HAE104.730.311.583804
2026-10-06HAE103.620.340.013878
2026-10-07HAE101.780.330.003952
2026-10-08HAE119.580.330.683955
2026-10-09HAE118.660.530.905670
2026-10-12HAE122.030.550.895844
2026-10-13HAE121.620.600.196064
2026-10-14HAE121.110.609.916048
2026-10-15HAE121.260.650.756226
2026-10-16HAE118.280.650.306217
2026-10-19HAE118.690.600.226088
2026-10-20HAE118.20.5911.256204
2026-10-21HAE117.050.590.176223
2026-10-22HAE116.180.590.006223
DateSymbolLatestP/C OIP/C VolTotal OI
22 items Current Page1 of 1




22 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-09-23HAE106.921.7106.65.31
2026-09-24HAE105.971.7108.15.31
2026-09-25HAE105.371.7108.65.31
2026-09-28HAE105.851.7111.15.31
2026-09-29HAE105.851.7110.15.31
2026-09-30HAE105.311.7108.95.31
2026-10-01HAE104.471.7108.25.31
2026-10-02HAE104.681.7108.65.31
2026-10-05HAE104.621.7109.85.31
2026-10-06HAE103.551.7107.55.31
2026-10-07HAE101.711.7106.05.31
2026-10-08HAE119.591.7149.45.31
2026-10-09HAE118.731.7108.55.31
2026-10-12HAE122.101.7116.65.31
2026-10-13HAE121.881.7109.55.31
2026-10-14HAE121.091.7108.75.31
2026-10-15HAE121.321.7109.25.31
2026-10-16HAE118.281.7104.25.31
2026-10-19HAE118.721.7110.85.31
2026-10-20HAE118.721.7110.85.31
2026-10-21HAE118.151.7108.85.31
2026-10-22HAE116.181.7108.15.31
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
22 items Current Page1 of 1




22 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-09-23HAE0.003.396.41
2026-09-24HAE0.003.396.41
2026-09-25HAE0.003.397.67
2026-09-28HAE0.003.407.67
2026-09-29HAE0.003.407.67
2026-09-30HAE0.003.407.67
2026-10-01HAE0.003.407.67
2026-10-02HAE0.003.407.67
2026-10-05HAE0.003.277.67
2026-10-06HAE0.003.277.67
2026-10-07HAE0.003.277.67
2026-10-08HAE0.003.277.67
2026-10-09HAE0.003.277.67
2026-10-12HAE0.003.366.81
2026-10-13HAE0.003.366.81
2026-10-14HAE0.003.366.81
2026-10-15HAE0.003.366.81
2026-10-16HAE0.003.366.81
2026-10-19HAE0.003.466.81
2026-10-20HAE0.003.466.81
2026-10-21HAE0.003.466.81
2026-10-22HAE0.003.466.81
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
22 items Current Page1 of 1

Last Quarter Act. EPS​

1.14

Avg. EPS Est. Current Quarter

1.29

Avg. EPS Est. Next Quarter

1.36

Insider Transactions

Institutional Transactions

3.46

Beta

0.65

Average Sales Estimate Current Quarter

345

Average Sales Estimate Next Quarter

357

Fair Value

92.04

Quality Score

70

Growth Score

76

Sentiment Score

82

Actual DrawDown %

6.1

Max Drawdown 5-Year %

-51

Target Price

124.5

P/E

56.67

Forward P/E

19.97

PEG

1.95

P/S

3.91

P/B

6.31

P/Free Cash Flow

18.15

EPS

2.05

Average EPS Est. Cur. Y​

5.31

EPS Next Y. (Est.)

5.78

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

7.12

Relative Volume

0.5

Return on Equity vs Sector %

-14.1

Return on Equity vs Industry %

0.5

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

108.1
◆ HAE Healthcare
$116.18
📉
Swing / Pullback
Buy the dip on strong trends
36 /100
WEAK
Trend
0/20
Pullback
10/25
Volume
11/15
Valuation
7/20
TP/AR
3/10
Options
5/10
RSI
59.7
Range 1M
67.9%
Sup Dist
0%
🚀
Momentum Growth
Ride accelerating trends
N/A
37 /100
WEAK
Momentum
5/25
Growth
11/30
Estimates
6/20
Inst/Vol
8/15
Options
7/10
EPS Yr
7.1%
EPS NY
9.5%
52W%
90.4%
💎
Long-Term Value
Quality companies, undervalued
N/A
0 /100
WEAK
🔴 SELL -0.1% upside
Quality
8/30
Valuation
1/30
Growth
10/25
Stability
6/10
LT Trend
1/5
Upside
-0.1%
Quality
70
MoS
-21%
HAE — P/E HistoricalMedical Instruments & Supplies
Haemonetics Corporation
Sector: Healthcare
Industry: Medical Devices
Employees: 3009
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. The company also offers treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, it provides hospital products comprising TEG 6s system, smallest cartridge-based viscoelastic analyzer that provides a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, the company offers Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries;vascular closure products comprise VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen; and transfusion management solutions. It sells its products through direct sales force and independent distributors. The company was founded in 1971 and is headquartered in Boston, Massachusetts.
HAE

Latest News

—
Caricamento notizie per HAE…
stock quote shares HAE – Haemonetics Corporation Stock Price stock today
news today HAE – Haemonetics Corporation stock forecast ,stock prediction 2023 2024 2025
marketwatch HAE – Haemonetics Corporation yahoo finance google finance
stock history HAE – Haemonetics Corporation invest stock market
stock prices HAE premarket after hours
ticker HAE fair value insiders trading